What is Ascentage Pharma Group International?
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 3.17B.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.